Patients entered into MRC AML trials are biologically representative of the totality of the disease in the UK

被引：5
作者：
Moorman, AV [1 ]
Roman, E
Cartwright, RA
Morgan, GJ
机构：
[1] Univ Leeds, Leukaemia Res Fund Ctr Clin Epidemiol, Leeds, W Yorkshire, England
[2] Leeds Gen Infirm, HMDS, Acad Unit Haematol & Oncol, Leeds, W Yorkshire, England
来源：
CLINICAL AND LABORATORY HAEMATOLOGY | 2002年 / 24卷 / 04期
关键词：
D O I：
10.1046/j.1365-2257.2002.00445.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：263 / 265
页数：3
相关论文
共 8 条
[1]   Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia [J].
Allan, JM ;
Wild, CP ;
Rollinson, S ;
Willett, EV ;
Moorman, AV ;
Dovey, GJ ;
Roddam, PL ;
Roman, E ;
Cartwright, RA ;
Morgan, GJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (20) :11592-11597
[2]   The PACE (population-adjusted clinical epidemiology) strategy: A new approach to multi-centred clinical research - Commentary [J].
Charlton, BG ;
Taylor, PRA ;
Proctor, SJ .
QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 1997, 90 (02) :147-151
[3]   The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1,612 patients entered into the MRC AML 10 trial [J].
Grimwade, D ;
Walker, H ;
Oliver, F ;
Wheatley, K ;
Harrison, C ;
Harrison, G ;
Rees, J ;
Hann, I ;
Stevens, R ;
Burnett, A ;
Goldstone, A .
BLOOD, 1998, 92 (07) :2322-2333
[4]  
Grimwade D, 2000, BLOOD, V96, p825A
[5]   Karyotype and age in acute myeloid leukemia. Are they linked? [J].
Moorman, AV ;
Roman, E ;
Willett, EV ;
Dovey, GJ ;
Cartwright, RA ;
Morgan, GJ .
CANCER GENETICS AND CYTOGENETICS, 2001, 126 (02) :155-161
[6]  
*MRC CLIN TRIAL SE, 2000, REP AD CHILDH LEUK W
[7]   Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults [J].
Smith, MT ;
Wang, YX ;
Kane, E ;
Rollinson, S ;
Wiemels, JL ;
Roman, E ;
Roddam, P ;
Cartwright, R ;
Morgan, G .
BLOOD, 2001, 97 (05) :1422-1426
[8]   A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial [J].
Wheatley, K ;
Burnett, AK ;
Goldstone, AH ;
Gray, RG ;
Hann, IM ;
Harrison, CJ ;
Rees, JKH ;
Stevens, RF ;
Walker, H .
BRITISH JOURNAL OF HAEMATOLOGY, 1999, 107 (01) :69-79
1